
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
ข้อมูลล่าสุด
US$19.91
+US$0.26 · +1.32%
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
ราคาปิดก่อนหน้า
US$19.91
+US$0.26 · +1.32%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
ช่วงราคารายวัน
ปัจจุบัน US$19.91
ช่วง 52 สัปดาห์
ปัจจุบัน US$19.91
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
61
ต่ำกว่ามูลค่า
ความเชื่อมั่น
64
เชิงบวก
ความเสี่ยง
34
ความเสี่ยงปานกลาง
โมเมนตัม
67
กำลังแข็งแกร่งขึ้น
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
ช่วงราคารายวัน
ปัจจุบัน US$19.91
ช่วง 52 สัปดาห์
ปัจจุบัน US$19.91
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 3.02B USD | 2.79B USD | 2.39B USD | 2.21B USD | 2.09B USD |
| ต้นทุนสินค้าขาย | 1.88B USD | 1.77B USD | 1.53B USD | 1.42B USD | 1.32B USD |
| กำไรขั้นต้น | 1.14B USD | 1.02B USD | 863.87M USD | 791.46M USD | 768.97M USD |
| การวิจัยและพัฒนา | 186.18M USD | 190.71M USD | 194.75M USD | 208.66M USD | 209.56M USD |
| การขาย ทั่วไป และธุรการ | 526.83M USD | 476.44M USD | 429.68M USD | 399.7M USD | 365.5M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 713M USD | 771.11M USD | 659.5M USD | 886.39M USD | 616.26M USD |
| ดอกเบี้ยจ่าย | 241.09M USD | 258.6M USD | 210.63M USD | 158.38M USD | 136.33M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 223.57M USD | 236.19M USD | 229.4M USD | 240.18M USD | 233.41M USD |
| รายได้จากการดำเนินงาน | 423.09M USD | 249.33M USD | 204.37M USD | −94.93M USD | 152.72M USD |
| รายได้สุทธิ | 72.06M USD | −116.89M USD | −83.99M USD | −129.99M USD | 10.62M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$23.20
โอกาสปรับขึ้น 16.52%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI97.43M0.00%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM80.33M0.10%78.74B USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB70.45M0.04%185.3B USD0.03%US$289.48+0.64%
Dimensional - US Small Cap ETFDFAS46.99M0.14%33.87B USD0.31%US$78.35+0.32%
Vanguard Morningstar Small-Cap Value ETFVBR44.79M0.07%68.2B USD0.05%US$234.43+0.22%
Invesco S&P SmallCap Momentum ETFXSMO43.09M1.50%2.87B USD0.35%US$81.75+0.57%
Vanguard Extended Market ETFVXF34.98M0.04%95.4B USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM33.47M0.21%15.84B USD0.03%US$53.45+0.17%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Dimensional - US Small Cap ETFDFAS
Vanguard Morningstar Small-Cap Value ETFVBR
Invesco S&P SmallCap Momentum ETFXSMO
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน